Integrated full-service Contract Research Organisation (CRO) and Consulting Expertise Driving Life Sciences Innovation
Biointelect is a globally recognised Australian consulting and advisory firm offering a unique blend of full-service Contract Research Organisation (CRO) capabilities and commercialisation consulting. With deep roots in the full health innovation ecosystem, Biointelect provides end-to-end support across the entire development pathway from early-stage research through to market access and health system integration.
Leverage our expertise and strategic project management to refine your innovative ideas into actionable and successful commercial projects.
Lay the essential foundations for commercial success by drawing on our knowledge of the life science ecosystem, regulatory and clinical pathways.
Navigate the challenges of bringing a therapy to market leveraging our broad cross-functional experience. Build vital knowledge to inform all stages of market readiness.
Secure your innovation’s long-term commercial viability as a successful resource that supports healthcare professionals and patients in need.
Our Proven Track Record
Some of our Clients include
CR2O provide leadership and operational excellence in conducting Phase I-IV clinical trials and their global network of experts.
CBE provide technical support as the experts in facility design, manufacturing, quality and good manufacturing practice (GMP) accreditation.
QNova Life Sciences provide direct FDA support through their US-based consultancy.
Discover Our Services
At Biointelect, we ensure you navigate the right path to market for new health technologies by providing industry-leading commercialisation consulting at each stage of the development pathway.
Our services extend from product development strategy, clinical affairs and director services, commercialisation and regulatory strategy, to market access pathways and government and health policy.
Discover the latest resources, news, white papers and policy position papers from the life science sector through the global lens of our Biointelect experts.
National incubator for vaccine and infectious diseases innovation opens for ‘Expression of Interest’ Applications Biointelect Venturer, a national incubator focused...
The Maternal Immunisation in Australia whitepaper was developed by Biointelect in collaboration with the Immunisation Foundation of Australia (IFA) and...
Brain cancer remains one of the most complex and devastating diseases impacting Australians. Biointelect supported Brain Tumour Alliance Australia (BTAA)...
Sydney, Australia – Biointelect, a leader in life sciences commercialisation, has been awarded a $32.9 million grant from the Australian...
This summary explores how antimicrobial resistance (AMR) is framed within Health Technology Assessment (HTA) frameworks worldwide and Australia’s unique role...
There is an identified need in Australia’s Vaccine Value Chain to boost vaccine development, translation, commercialisation and access. Globally, there...
The Maternal Immunisation in Australia whitepaper was developed by Biointelect in collaboration with the Immunisation Foundation of Australia (IFA) and...
Brain cancer remains one of the most complex and devastating diseases impacting Australians. Biointelect supported Brain Tumour Alliance Australia (BTAA)...
Horizon scanning is a process or system which seeks to systematically and proactively identify current, new, and emerging health technologies...
Macquarie Park Innovation District (MPID) is Australia’s first innovation district, home to the world class Macquarie University, headquarters of multi-national...
Get in Touch
Wherever you are in your new product journey, Biointelect’s unique expertise across each stage of the life science value chain means we are ready to bring your innovative life science to market.
Take the next steps in advancing healthcare for all by contacting our team of local Australian and global life science experts today.
